Overexpression of Mcl-1 has been implicated in resistance to both chemotherapy and to BH3-mimetics targeting Bcl-2 and Bcl-XL43, arousing considerable interest toward Mcl-1 as a therapeutic target in AML. The gene discussed is BCL2; the disease is acute myeloid leukemia.